Jin D, Wang YW, Lin ZM, Li C, Li M. Medical dilemma: Programmed death 1 blockade (sintilimab) therapy in patients suffering from tumours combined with psoriasis. World J Cardiol 2024; 16(9): 546-549 [PMID: 39351336 DOI: 10.4330/wjc.v16.i9.546]
Corresponding Author of This Article
Ming Li, MD, Chief Doctor, Staff Physician, Department of Rheumatology, Weifang People’s Hospital, No. 151 Guangwen Street, Kuiwen District, Weifang 261000, Shandong Province, China. lalwlm@aliyun.com
Research Domain of This Article
Dermatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Cardiol. Sep 26, 2024; 16(9): 546-549 Published online Sep 26, 2024. doi: 10.4330/wjc.v16.i9.546
Medical dilemma: Programmed death 1 blockade (sintilimab) therapy in patients suffering from tumours combined with psoriasis
Di Jin, Yu-Wei Wang, Zhi-Min Lin, Chen Li, Ming Li
Di Jin, Ming Li, Department of Rheumatology, Weifang People’s Hospital, Weifang 261000, Shandong Province, China
Yu-Wei Wang, Department of Cardiology, Yidu Central Hospital of Weifang, Weifang 261000, Shandong Province, China
Zhi-Min Lin, Third Affiliated Hospital, Beijing University of Chinese Medicine, Beijing 100020, China
Chen Li, Department of Rheumatology, Fangshan Hospital, Beijing University of Chinese Medicine, Beijing 102400, China
Co-first authors: Di Jin and Yu-Wei Wang.
Co-corresponding authors: Ming Li and Chen Li.
Author contributions: Jin D and Wang YW prepared the manuscript and contributed equally to this article, ensuring a cohesive presentation of the research findings; Jin D and Lin ZM were responsible for the meticulous analysis and interpretation of the case, providing essential insights that underpinned the study's conclusions; Li C and Li M were at the helm of conceptualizing and designing the research ideas, setting the stage for the study with their innovative and well-defined framework; All authors have read and approved the final manuscript, with Jin D and Wang YW recognized as co-first authors for their significant contributions to the manuscript preparation, and the collaborative efforts of the team were instrumental in bringing the research to fruition.
Supported byWeifang Health Commission's Scientific Research Program, No. WFWSJK-2023-222 and No. WFWSJK-2023-240; and the Weifang Young Medical Talent Support Project.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ming Li, MD, Chief Doctor, Staff Physician, Department of Rheumatology, Weifang People’s Hospital, No. 151 Guangwen Street, Kuiwen District, Weifang 261000, Shandong Province, China. lalwlm@aliyun.com
Received: June 15, 2024 Revised: August 16, 2024 Accepted: September 10, 2024 Published online: September 26, 2024 Processing time: 96 Days and 8.1 Hours
Abstract
Tumour immunotherapy represented by immune checkpoint inhibitors (ICIs) has greatly improved the overall prognosis of patients with malignant tumours, and is regarded as an important breakthrough in the field of medicine in recent years. ICIs have gradually become the core of tumour therapy and are increasingly used in the clinic. In order to achieve early clinical prediction and management of immune-related adverse events (irAEs), it is still necessary to perform further research on the mechanisms, risk factors, and predictors of irAE occurrence in the future. Zhou et al describe the consultation of a patient with advanced gastric cancer combined with chronic plaque psoriasis. This case provides an important reference for the use of programmed cell death protein-1 (PD-1) inhibitors in patients of tumours combined with chronic plaque psoriasis. This case also highlights that screening of high-risk groups for irAEs is critical before applying PD-1 inhibitors to patients with chronic psoriasis combined with tumours. PD-1 inhibitors are new and potent antineoplastic agents that can cause serious immune-related adverse events such as toxic epidermal necrolysis release and psoriasis. Glucocorticosteroids are the first-line agents for irAEs. The incidence of rheumatic irAEs may be higher in reality, which will inevitably become a new challenge for rheumatologists and dermatologists.
Core Tip: The major strategies for dealing with immune-related adverse events should include scientific awareness, early diagnosis and graded management. The important direction of tumour immunotherapy research is how to reduce the adverse effects of immunotherapy and can improve the quality of patient survival. The correlation between programmed cell death protein-1 inhibitors and chronic psoriasis is gradually receiving more and more attention, and how to screen high-risk populations in the future, as well as to give the necessary and effective preventive therapeutic measures still need to be further explored.
